Dahlia Haddad
Optometrist · Goodlettsville, TNNPI 1962852608
Payments from drug & device makers
Across 91 payments — averaging $42.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$693
- AbbVie$600
- Bausch & Lomb Americas Inc.$263
- Novartis$258
- Glaukos Corporation$253
- Rxsight Inc$226
- plus $2K from 16 others
What the payments were for
- Food & beverage$3,831100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 20 | $693 |
| AbbVie(2 entities) | 18 | $600 |
| Bausch & Lomb Americas Inc. | 5 | $263 |
| Novartis | 10 | $258 |
| Glaukos Corporation | 6 | $253 |
| Rxsight Inc | 2 | $226 |
| Carl Zeiss Meditec, Inc. | 2 | $196 |
| Aerie Pharmaceuticals, Inc. | 2 | $193 |
| Dompe US, Inc. | 3 | $184 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $141 |
| Harrow Eye, LLC | 1 | $125 |
| Tarsus Pharmaceuticals, Inc. | 1 | $121 |
| Coopervision Inc. | 3 | $118 |
| Sight Sciences, Inc. | 2 | $113 |
| Johnson & Johnson Vision Care, Inc. | 1 | $111 |
| Biotissue Holdings Inc. | 5 | $100 |
| Thea Pharma Inc. | 2 | $44 |
| Oyster Point Pharma, Inc. | 2 | $37 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $23 |
| Omeros Corporation | 1 | $15 |
| Sun Pharmaceutical Industries Inc. | 1 | $11 |
| Lensar, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$228
- RXSIGHT CONTACT LENS$226
- RXSIGHT INJECTOR CARTRIDGE$226
- RXSIGHT INJECTOR HANDPIECE$226
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$226
- LIGHT ADJUSTABLE LENS (LAL)$226
- VEVYE$125
- Oxervate$125
- DURYSTA$125
- XEN GLAUCOMA TREATMENT SYSTEM$125
- TRYPTYR$123
- XDEMVY$121
- XIIDRA$120
- CATALYS SYSTEM$119
- Tecnis IOL$119
- Tecnis Simplicity$119
- iDoseTR$118
- Rhopressa$118
- Rocklatan$118
- TRAVATAN Z$113
How this compares
$3,831 in reported general payments places this provider in the 85th percentile of 1,122 optometrist providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 74 | $38,721 |
| XiidraLifitegrast | 17 | $22,811 |
| RhopressaNetarsudil Mesylate | 49 | $21,420 |
| Prednisolone Acetate | 359 | $15,765 |
| RocklatanNetarsudil Mesylat/Latanoprost | 34 | $14,261 |
| Ketorolac Tromethamine | 334 | $12,357 |
| VyzultaLatanoprostene Bunod | 27 | $10,268 |
| CombiganBrimonidine Tartrate/Timolol | 20 | $8,889 |
| MoxifloxacinMoxifloxacin Hcl | 294 | $8,184 |
| TyrvayaVarenicline Tartrate | 12 | $7,261 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 23 | $5,829 |
| Latanoprost | 305 | $4,103 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 47 | $2,474 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 103 | $2,225 |
| Dorzolamide Hcl | 53 | $1,005 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $600 | $47,61094 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $193 | $35,68183 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $263 | $33,07844 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $37 | $7,26112 claims |
| AlconSimbrinza | $693 | $5,82923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,122 optometrist providers in Tennessee.
Other optometrist in Goodlettsville
- Kathryn BarbericGoodlettsville$7K
- David EvansMemphis$7.8M
- Bradley HinesMemphis$3M
- Christopher LievensMemphis$2.9M
- Peter van HovenBrentwood$402K
- Whitney HauserMemphis$330K
- Richard DurocherNashville$280K
- Torrey CarlsonKingsport$192K
- Frances BynumMartin$162K
- Melvin FriedmanMemphis$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.